Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

1. Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches.Pharmaceutics · 2024
   Review
2. The Urinary Microbiome: Role in Bladder Cancer and Treatment.Diagnostics (Basel, Switzerland) · 2022
   Review
3. New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.Cells · 2022
   Review
4. Bacillus Calmette-Guérin Immunotherapy for Cancer.Vaccines · 2021
   Review
5. Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients.Cancers · 2020
   Article
6. The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness.Bladder cancer (Amsterdam, Netherlands) · 2020
   Review
7. Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.BioMed research international · 2020
   Article
8. Mechanisms of BCG immunotherapy and its outlook for bladder cancer.Nature reviews. Urology · 2018
   Review
9. Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2018
   Article
10. Inflammatory microenvironment in the initiation and progression of bladder cancer.Oncotarget · 2017
    Review
11. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.Oncotarget · 2016
    Article
12. Future directions in bladder cancer immunotherapy: towards adaptive immunity.Immunotherapy · 2016
    Review
13. Immunological basis in the pathogenesis and treatment of bladder cancer.Expert review of clinical immunology · 2015
    Review
14. BCG immunotherapy for bladder cancer--the effects of substrain differences.Nature reviews. Urology · 2013
    Review
15. Bacille Calmette-Guérin: An ophthalmic perspective.Survey of ophthalmology
    Review
16. Trial Watch: Toll-like receptor agonists in oncological indications.Oncoimmunology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract